Additionally, the therapeutic potential of targeting this axis is being substantiated in clinical settings, such as the FRACTAL trial, which is evaluating the CX3CR1 antagonist KAND567 in patients with myocardial infarction [93]. Here, CX3CR1 is linked to myocardial infarction.